Overview
Promote the canine mitral valve intervention device to the world
Recently, Zhejiang Hongyu Medical Technology Co., Ltd. has completed 30 million a rounds of financing led by CITIC Industrial Fund (with Lize Fund). The raised funds will be used to expand the global market of Hongyu pet dog mitral valve intervention device.
Highlights
Hongyu is committed to the global interventional treatment of dog heart disease. It is the first R & D enterprise specializing in the interventional treatment of dog heart in the world, and fills in the gap of the global heart treatment equipment for dog. At present, it is cooperating with many top veterinary hospitals in the world, and has entered the clinical application stage in more than 30 developed countries, such as the United States, the United Kingdom, France, Germany, Japan, etc. it is expected to achieve large-scale sales in the second half of the year.
Hongyu's Shanghai Xinyu pet hospital is the first heart surgery center in China. It will provide training for the world's top teams in the field of pet dog heart disease diagnosis and treatment and minimally invasive interventional surgery. To become a minimally invasive interventional treatment center for mitral valve in Asia and the world.
Mitral regurgitation is very common in small dogs in the elderly, with an incidence rate of 20-30%. In the United States alone, there are about 7.18 million mitral regurgitated dogs. The incidence rate increases with age. In dogs with mitral valve insufficiency, there are characteristic night cough, night asthma, weakness, exercise intolerance or fatigue after agitation, prolonged recovery time, serious purple tongue color, and syncope. The survival time of dogs with severe mitral regurgitation is only 3-6 months.
Traditional drug control effect is general, can only alleviate symptoms, can not be cured, the disease will continue to aggravate. The cost of medicine varies from 2000 to 4000 yuan per month. Or surgical thoracotomy. At present, only a few teams in the world have completed individual cases, which can not be widely promoted.
Hongyu v-clamp minimally invasive surgery has the advantages of high safety, small trauma, fast recovery, no need for cardiac arrest and cardiopulmonary bypass, 2-3cm incision in the precordial area, puncture the heart into the device to complete mitral valve repair, reduce mitral regurgitation, and provide a new technical scheme for the treatment of canine mitral regurgitation. The technology was developed by Shanghai Hanyu medical and Ge Junbo, academician of Zhongshan Hospital Affiliated to Fudan University. It has completed nearly 100 clinical operations in the field of human medicine and achieved great success.
Details
It is estimated that there are 30 million cases of mitral regurgitation in the world, which need to be treated urgently. The price of overseas products is 12000 US dollars / set. Hongyu medical is about to open a blue ocean market with a scale of 100 billion. By the end of 2020, Hongyu production and R & D building, with a total area of more than 20000 square meters, is about to start construction. It can be predicted that the success of v-clamp in the treatment of canine heart disease will surely achieve good social value and market value.
Hongyu will shoulder the national responsibility, actively promote the global application of v-clamp, and open a new era of global pet dog mitral regurgitation treatment.
